Cargando…

Effect of midazolam on delirium in critically ill patients: a propensity score analysis

OBJECTIVE: To observe the association between exposure to midazolam within 24 hours prior to delirium assessment and the risk of delirium. METHODS: We performed a systematic cohort study with two sets of cohorts to estimate the relative risks of outcomes among patients administered midazolam within...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, He-Jie, Yuan, Rui-Xia, Zhang, Jun-Zhi, Chen, Jia-Hui, Hu, An-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044793/
https://www.ncbi.nlm.nih.gov/pubmed/35466751
http://dx.doi.org/10.1177/03000605221088695
_version_ 1784695181071613952
author Shi, He-Jie
Yuan, Rui-Xia
Zhang, Jun-Zhi
Chen, Jia-Hui
Hu, An-Min
author_facet Shi, He-Jie
Yuan, Rui-Xia
Zhang, Jun-Zhi
Chen, Jia-Hui
Hu, An-Min
author_sort Shi, He-Jie
collection PubMed
description OBJECTIVE: To observe the association between exposure to midazolam within 24 hours prior to delirium assessment and the risk of delirium. METHODS: We performed a systematic cohort study with two sets of cohorts to estimate the relative risks of outcomes among patients administered midazolam within 24 hours prior to delirium assessment. Propensity score matching was performed to generate a balanced 1:1 matched cohort and identify potential prognostic factors. The outcomes included the odds of delirium, mortality, length of intensive care unit stay, length of hospitalization, and odds of being discharged home. RESULTS: A total of 78,364 patients were included in this study, of whom 22,159 (28.28%) had positive records. Propensity matching successfully balanced covariates for 9348 patients (4674 per group). Compared with no administration of midazolam, midazolam administration was associated with a significantly higher risk of delirium, higher mortality, and a longer intensive care unit stay. Patients treated with midazolam were relatively less likely to be discharged home. There was no significant difference in hospitalization duration. CONCLUSIONS: Midazolam may be an independent risk factor for delirium in critically ill patients.
format Online
Article
Text
id pubmed-9044793
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90447932022-04-28 Effect of midazolam on delirium in critically ill patients: a propensity score analysis Shi, He-Jie Yuan, Rui-Xia Zhang, Jun-Zhi Chen, Jia-Hui Hu, An-Min J Int Med Res Retrospective Clinical Research Report OBJECTIVE: To observe the association between exposure to midazolam within 24 hours prior to delirium assessment and the risk of delirium. METHODS: We performed a systematic cohort study with two sets of cohorts to estimate the relative risks of outcomes among patients administered midazolam within 24 hours prior to delirium assessment. Propensity score matching was performed to generate a balanced 1:1 matched cohort and identify potential prognostic factors. The outcomes included the odds of delirium, mortality, length of intensive care unit stay, length of hospitalization, and odds of being discharged home. RESULTS: A total of 78,364 patients were included in this study, of whom 22,159 (28.28%) had positive records. Propensity matching successfully balanced covariates for 9348 patients (4674 per group). Compared with no administration of midazolam, midazolam administration was associated with a significantly higher risk of delirium, higher mortality, and a longer intensive care unit stay. Patients treated with midazolam were relatively less likely to be discharged home. There was no significant difference in hospitalization duration. CONCLUSIONS: Midazolam may be an independent risk factor for delirium in critically ill patients. SAGE Publications 2022-04-25 /pmc/articles/PMC9044793/ /pubmed/35466751 http://dx.doi.org/10.1177/03000605221088695 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Retrospective Clinical Research Report
Shi, He-Jie
Yuan, Rui-Xia
Zhang, Jun-Zhi
Chen, Jia-Hui
Hu, An-Min
Effect of midazolam on delirium in critically ill patients: a propensity score analysis
title Effect of midazolam on delirium in critically ill patients: a propensity score analysis
title_full Effect of midazolam on delirium in critically ill patients: a propensity score analysis
title_fullStr Effect of midazolam on delirium in critically ill patients: a propensity score analysis
title_full_unstemmed Effect of midazolam on delirium in critically ill patients: a propensity score analysis
title_short Effect of midazolam on delirium in critically ill patients: a propensity score analysis
title_sort effect of midazolam on delirium in critically ill patients: a propensity score analysis
topic Retrospective Clinical Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044793/
https://www.ncbi.nlm.nih.gov/pubmed/35466751
http://dx.doi.org/10.1177/03000605221088695
work_keys_str_mv AT shihejie effectofmidazolamondeliriumincriticallyillpatientsapropensityscoreanalysis
AT yuanruixia effectofmidazolamondeliriumincriticallyillpatientsapropensityscoreanalysis
AT zhangjunzhi effectofmidazolamondeliriumincriticallyillpatientsapropensityscoreanalysis
AT chenjiahui effectofmidazolamondeliriumincriticallyillpatientsapropensityscoreanalysis
AT huanmin effectofmidazolamondeliriumincriticallyillpatientsapropensityscoreanalysis